FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction

Pharmaceutical Research

Volumn 13, Issue 1, 1996, Pages 137-140

  Tokunaga, Yuji ^a   Alak, Ala M ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

FK506; Hepatic dysfunction; HPLC ELISA; Immunoreactive metabolites; Liver transplantation; Tacrolimus

Indexed keywords

DRUG METABOLITE; TACROLIMUS;

ARTICLE; BLOOD ANALYSIS; CASE REPORT; DRUG METABOLISM; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOREACTIVITY; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; CHILD; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 0029865392     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016002005912     Document Type: Article

References (12)

1. T. Goto, T. Kino, H. Hatanaka, M. Nishiyama, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant. Proc. 19:4-8 (1987).
2. T. Goto, T. Kino, H. Hatanka, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka. FK 506: Historical perspectives. Transplant. Proc. 23:2713-2717 (1991).
3. K. Tamura, M. Kobayashi, K. Hashimoto, K. Kojima, K. Nagase, K. Iwasaki, T. Kaizu, H. Tanaka, and M. Niwa. A highly sensitive method to assay FK-506 levels in plasma. Transplant. Proc. 19:23-29 (1987).
4. F. C. Granier, J. Loczkiw, M. Bergmann, S. Luntra, M. Morrison, D. Blonski, K. Shoemaker, and M. Kobayashi. A whole blood FK506 assay for the IMx® analyzer. Transplant. Proc. 23: 2748-2749 (1991).
5. U. Christians, C. Kruse, R. Kownatzki, H. M. Schiebel, R. Schwinzer, M. Sattler, R. Schottman, A. Linck, V. M. F. Almeida, F. Braun, and K.-Fr. Sewing. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant. Proc. 23: 940-941 (1991).
6. A.-K. Gonschior, U. Christians, F. Braun, M. Winkler, A. Linck, J. Baumann, and K.-Fr. Sewing. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.e.-MS and microparticle enzyme immunoassay (MEIA). Br. J. Clin. Pharmacol. 38: 567-571 (1994).
7. S. H. Vincent, B. V. Karanam, S. K. Painter, and S.-H. L. Chiu. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch. Biochem. Biophys. 294: 454-460 (1992).
8. T. Shiraga, H. Matsuda, K. Nagase, K. Iwasaki, K. Noda, H. Yamazaki, T. Shimada, and Y. Funae. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47: 727-735 (1994).
9. K. Iwasaki, T. Shiraga, K. Nagase, Z. Tozuka, K. Noda, S. Sakuma, R. Fujitsu, K. Shimatani, A. Sato, and M. Fujioka. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab. Dispos. 21: 971-977 (1993).
10. R. D'Ambrosio, N. Girzaitis, and W. J. Jusko. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. Ther. Drug Monit. 15:414-426 (1993).
11. K. Iwasaki, T. Shiraga, H. Matsuda, K. Nagase, Y. Tokuma, T. Hata, Y. Fijii, S. Sakuma, T. Fujitsu, A. Fujikawa, K. Shimatani, A. Sato, and M. Fujioka. Further metabolism of FK506 (tacrolimus). Indentification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab. Dispos. 23:28-34 (1995).
12. A.-K. Gonschior, U. Christians, M. Winkler, A. Linck, J. Bauman, K.-Fr. Sewing. Tacrolimus (FK506) metabolite pattern in blood from liver and kidney transplant patients. Clin. Pharmacol. Ther. submitted, 1995.